Navigation Links
Lentigen Corporation Announces Relocation to New Facility
Date:9/9/2008

GAITHERSBURG, Md., Sept. 9 /PRNewswire/ -- Lentigen Corporation announced today that it has relocated its corporate headquarters, research labs and manufacturing from the University of Maryland Baltimore County TechCenter, to 910 Clopper Road, Suite 200 South Building, Gaithersburg, MD 20878 (Tel: 301.527.4200).

Located along Maryland's I-270 technology corridor, the almost 26,000 square-foot facility will accommodate Lentigen's future growth needs as the leading developer and manufacturer of lentiviral vectors (LVs) and proteins for a wide range of clinical and research applications. Two self-contained suites measuring 4,900 square feet will allow the simultaneous production of both LVs and proteins in compliance with FDA-regulated current good manufacturing practices (cGMP).

"We appreciated the opportunity afforded to grow our company at the TechCenter, but the move to our new facility is a significant step forward in our evolution as a biotech company," stated Tim Ravenscroft, Lentigen's CEO. "The new facility provides an opportunity to expand our research programs. More importantly, the addition of the cGMP manufacturing suites will allow us to manage our programs from the labs through manufacturing to the clinic. We plan to manufacture lentiviral products for clinical trials during 2009 and we will have capacity to handle manufacturing projects for collaborators as the market for lentiviral products expands."

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing lentiviral vector-based products across a broad spectrum of bench to clinical applications. Partnerships include The National Institutes of Health, The University of Pennsylvania, Invitrogen, ThermoFisher Scientific and The U.S. Army. For further information, visit http://www.lentigen.com

Contact:

Richard Lewis Communications, Inc.

212-827-0020

Cecelia Heer - Investors

cheer@rlcinc.com

Megan Dubrowski - Media

mdubrowski@rlcinc.com


'/>"/>
SOURCE Lentigen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VIRxSYS and Lentigen Announce Litigation Settlement
2. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
3. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
4. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
5. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
6. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
7. Lentigen Appoints Jim Meade as Vice President of Corporate Development
8. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a United States multicenter, prospective clinical study that demonstrates the accuracy ... test capable of identifying clinically significant acute bacterial and viral respiratory tract ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and ... Labs ), Inc. has been selected for membership in ARCS Alumni Hall ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... the implantation and pregnancy rates in frozen and fresh in vitro fertilization ... progesterone and maternal age to IVF success. , After comparing the results from ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... March 30, 2017 The research team of ... three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae ... realm of speed and accuracy for use in identification, crime investigation, ... cost. ... A research ...
Breaking Biology News(10 mins):